Cardiology

At ACC.25, Boer highlights treatment gaps in the US for lipid control in a high-risk ASCVD population.

Ahmad Masri, MD, MS, discusses how new options change the historic approach to the treatment of newly diagnosed ATTR-CM.

Daniel Judge, MD, discusses data from a prespecified analysis of ATTRibute-CM examining the effects of acoramidis with and without concomitant tafamidis use.

The first quarter of 2025 saw approvals in diabetes, depression, kidney disease, and pain, among others. Read more about high-impact approvals of Q1 now.

Patients with PAH saw a 76% reduction in the composite of morbidity and mortality outcomes with sotatercept treatment.

Ahmad Masri, MD, MS, discusses data detailing the effects of aficamten in oHCM from the FOREST-HCM OLE study at ACC.25.

Vallerie Mclaughlin, MD, discusses the ZENITH trial and its historic effects of sotatercept on mortality, transplant risk, and more in PAH.

At ACC.25, Robert S. Rosenson, MD, discusses the efficacy and safety of solbinsiran, an ANGPTL3 inhibitor, in a population with mixed dyslipidemia.

Despite failing to achieve significance for its primary endpoint, investigators suggest the trial further demonstrates the potential of cell therapy in HFrEF.

Justin Mark, MD, discusses an analysis of the FIGHT trial looking at racial and ethnic differences in heart failure outcomes.

Jose Lopez, MD, discusses findings and perspective into racial and ethnic differences in DbCM from the ARISE-HF trial.

Ruff discusses a new analysis of AZALEA-TIMI 71 at ACC.25, which shows that the novel Factor XI inhibitor significantly lowered bleeding in elderly patients.

Hosts break down the STRIDE and SOUL trial results and reflect on how they might inform treatment strategies in the respective patient populations.

Steve Nissen, MD, discusses the phase 2 ALPACA trial and how it informs the potential of lepodisiran for lowering Lp(a).

Pulse oximeter bias was less negative in darkly pigmented skin, suggesting a difference in performance across skin pigment categories.

Phase 2 data at ACC.25 provide further insight into the effects of lepodisiran on serum Lp(a) and other biomarkers of risk.

Intravenous iron supplementation was safe but showed mixed improvement in cardiovascular outcomes in the FAIR-HF2 trial at ACC.25.

Dapagliflozin lowered the incidence of all-cause death or worsening of heart failure versus standard care in the DapaTAVI trial at ACC.25.

A secondary analysis of FINEARTS-HF found consistent efficacy of finerenone on heart failure events and cardiovascular death, irrespective of AF status.

Bhatt examines the potential reversal of the antiplatelet effects of ticagrelor with bentracimab in the REVERSE-IT trial.

FARES-II trial shows 4-factor PCC is safer, reduces bleeding, transfusions, and complications vs frozen plasma in cardiac surgery.

Four-year results from SOUL at ACC.25 were the first to test the cardiovascular benefits of an oral GLP-1 RA in high-risk type 2 diabetes.

Data from the REVERSE-IT trial provide vital insight into the efficacy and safety of bentracimab as an FDA decision looms on the horizon.

The WARRIOR trial provides insight into intensive medical therapy in women with INOCA, but investigators caution limitations hinder the applicability of results.